Herantis Pharma Oyj Asset Resilience Ratio
Herantis Pharma Oyj asset resilience ratio. Herantis Pharma Oyj (HRTIS) has an Asset Resilience Ratio of 89.18% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Herantis Pharma Oyj defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Herantis Pharma Oyj (2012–2024)
Asset resilience ratio of Herantis Pharma Oyj from 2012 to 2024. This chart shows how Herantis Pharma Oyj's Asset Resilience Ratio has changed over time. Read total liabilities of Herantis Pharma Oyj for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Herantis Pharma Oyj's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Herantis Pharma Oyj.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €446.00K | 8.72% |
| Short-term Investments | €4.11 Million | 80.46% |
| Total Liquid Assets | €4.56 Million | 89.18% |
Asset Resilience Insights
- Very High Liquidity: Herantis Pharma Oyj maintains exceptional liquid asset reserves at 89.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Herantis Pharma Oyj Industry Peers by Asset Resilience Ratio
Compare Herantis Pharma Oyj's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Herantis Pharma Oyj Asset Resilience Ratio by Year (2012–2024)
Herantis Pharma Oyj asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for Herantis Pharma Oyj.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 83.02% | €2.13 Million ≈ $2.50 Million |
€2.57 Million ≈ $3.01 Million |
-13.16pp |
| 2023-12-31 | 96.18% | €6.49 Million ≈ $7.59 Million |
€6.75 Million ≈ $7.89 Million |
+0.06pp |
| 2022-12-31 | 96.13% | €5.99 Million ≈ $7.00 Million |
€6.23 Million ≈ $7.29 Million |
+14.98pp |
| 2020-12-31 | 81.15% | €13.32 Million ≈ $15.58 Million |
€16.42 Million ≈ $19.20 Million |
+72.25pp |
| 2019-12-31 | 8.90% | €985.24K ≈ $1.15 Million |
€11.07 Million ≈ $12.94 Million |
-11.62pp |
| 2018-12-31 | 20.52% | €1.47 Million ≈ $1.71 Million |
€7.15 Million ≈ $8.36 Million |
-25.38pp |
| 2017-12-31 | 45.90% | €5.31 Million ≈ $6.21 Million |
€11.57 Million ≈ $13.53 Million |
+25.84pp |
| 2016-12-31 | 20.06% | €2.05 Million ≈ $2.39 Million |
€10.21 Million ≈ $11.93 Million |
-15.43pp |
| 2015-12-31 | 35.49% | €5.00 Million ≈ $5.85 Million |
€14.09 Million ≈ $16.47 Million |
+4.98pp |
| 2014-12-31 | 30.51% | €9.00 Million ≈ $10.52 Million |
€29.49 Million ≈ $34.48 Million |
-- |
| 2012-12-31 | 0.00% | €0.00 ≈ $0.00 |
€2.21 Million ≈ $2.59 Million |
-- |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more